

THURSDAY, 27 JUNE 2019

16:30 – 18:30 **Plenary Hall Saphir**

16:30 – 16:45 **Welcome Address**

Opening Session

Chairs:

Rifaat Safadi, *Hadassah Hebrew University, Israel*

Quentin Anstee, *Newcastle University, UK*

16:45 **Keynote Lecture:**

What is NAFLD - NASH and How it is Defined?

• **Jean-Francois Dufour**, *University of Bern, Switzerland*

17:15 Short break

17:20 – 18:30 **Debate:**

Should I be Looking for NASH in My Clinic?

17:20 PRO - **Jerome Boursier**, *Angers University Hospital, France*
vs.

17:40 CON - **Mark Walker**, *Newcastle University, UK*

18:00 **Open Discussion and Vote (30 minutes)**

18:30 – 20:00 Exhibition & Networking Area

18:30 – 20:00 Networking Reception

FRIDAY, 28 JUNE 2019

08:30 – 11:00 Plenary Hall Saphir

08:30 – 09:00 **Keynote lecture:**

Chair:

Arun Sanyal, *Virginia Commonwealth University, USA*

Biomarkers in NAFLD - If Not a Biopsy, What - and Why?

• **Quentin Anstee**, *Newcastle University, UK*

09:00 – 11:00 **Session 1: What Tools Do We Have to Assess Disease Severity in NAFLD**

Chairs:

Lawrence Serfaty, *University of Strasbourg, France*

Stefan Neubauer, *Oxford University, UK*

Blood Tests

09:00

Routine Blood Tests and Simple Scores in NAFLD

• **Salvatore Petta**, *University of Palermo, Italy*

09:20

New Technologies: Metabolomics, Genomics & Collagen Biomarkers

• **Detlef Schuppan**, *Institute of Translational Immunology, Germany*

MRI and Ultrasound

09:40

How to Use Imaging to Evaluate NASH in the Clinic – Practical Approaches for Use in the Real World?

• **Manuel Romero Gomez**, *Institute of Biomedicine of Seville, Spain*

10:00

Ultrasound-Based Elastography Techniques: TE, ARFI & SSI

• **Laurent Castera**, *University of Paris-VII, France*

10:20

MR-Based Assessment of Inflammation and Fibrosis

• **Stefan Neubauer**, *Oxford University, UK*

10:40

Panel Discussion (20 minutes)

11:00 – 11:30 Exhibition & Networking Area/ Rubin & Aquamarin Poster Area

11:00 – 11:30

Coffee break, Exhibition & Poster Viewing

Oral Presentations of selected Abstracts of Excellence

See page 20 for details.

11:30 – 13:15 Plenary Hall Saphir

11:30 - 12:00 **Keynote Lecture:**

Chair:

Rifaat Safadi, *Hadassah Hebrew University, Israel*

Global Epidemiology & Outcomes of the NAFLD

- **Zobair Younossi**, *Inova Fairfax Hospital, USA*

12:00 – 13:15 **Session 2: Screening - How Should I Evaluate NASH in My Clinic?**

Chairs:

Manuel Romero Gomez, *Institute of Biomedicine of Seville, Spain*

Zobair Younossi, *Inova Fairfax Hospital, USA*

12:00 **Gastro/ Hepatologist Perspective**

- **Lawrence Serfaty**, *University of Strasbourg, France*

12:20 **Diabetologist Perspective**

- **Gianluca Perseghin**, *University of Milano-Bicocca, Italy*

Case Presentation

12:40 **Identification of patients with advanced fibrosis – a case from my clinic!**

Leonard Kaps, *University Medical Center Mainz, Germany*

12:50 **Panel Discussion (25 minutes)**

13:15 – 14:15 Exhibition & Networking Area/ Rubin & Aquamarin Poster Area

13:15 – 14:15 Lunch Break, Exhibition & Poster Viewing

14:15 – 15:40	Plenary Hall Saphir
14:15 – 15:40	<p>Session 3: Treating the Metabolic Syndrome in Patients with NAFLD</p> <p>Chairs:</p> <p>Arun Sanyal, <i>Virginia Commonwealth University, USA</i></p> <p>Gianluca Perseghin, <i>University of Milano-Bicocca, Italy</i></p>
14:15	<p>Medical Therapy for T2DM</p> <ul style="list-style-type: none"> • Michael Roden, <i>German Center of Diabetology, Germany</i>
14:40	<p>Medical Therapy for Dyslipidaemia</p> <ul style="list-style-type: none"> • Dirk Muller-Wieland, <i>Aachen University Hospital, Germany</i>
15:05	<p>Case Presentation:</p> <p>Optimization of glucose control in a NASH patient with type 2 diabetes</p> <p>Sabine Kahl, <i>German Diabetes Center, Germany</i></p>
15:15	Panel Discussion (25 minutes)
15:40 – 16:10	Exhibition & Networking Area/ Rubin & Aquamarin Poster Area
15:40 – 16:10	<p>Coffee Break, Exhibition & Poster Viewing</p> <p>Oral Presentations of selected Abstracts of Excellence</p> <p>See page 21 for details.</p>



16:10 – 18:00 Plenary Hall Saphir

16:10 – 18:00 **Session 4: Treating NAFLD in Patients with the Metabolic Syndrome: Current Options**

Chairs:

Salvatore Petta, *University of Palermo, Italy*

Philip Newsome, *University of Birmingham, UK*

16:10 **Dietary Management**

- **Shira Zelber Sagi**, *Tel Aviv Medical Center, and School of Public Health, the University of Haifa, Israel*
-

16:30 **Alcohol in NAFLD: An Oxymoron or an Important Cofactor?**

- **Philip Newsome**, *University of Birmingham, UK*
-

16:50 **Current Available Pharmacological Therapeutic Options for NAFLD Using Drugs Available Today**

- **Kris Kowdley**, *Swedish Medical Center, USA*
-

17:10 **Bariatric Surgery for NAFLD**

- **Sebastian Mueller**, *University of Heidelberg, Germany*
-

Case Presentation

17:30 **L-liver on O-liver**

Yael Milgrom, *Hadassah Hebrew University, Israel*

17:40 **Panel Discussion (20 minutes)**

18:00 – 19:30 Rubin & Aquamarin Poster Area

18:00 – 19:30 Poster Presentation Happy Hour

SATURDAY, 29 JUNE 2019

08:30 – 10:30 Plenary Hall Saphir

08:30 – 10:30 Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow

Chairs:

Michael Roden, *German Center of Diabetology, Germany*

Ramy Younes, *University of Turin, Italy*

08:30 Keynote Lecture:

NAFLD Pathophysiology: Targets for Novel Treatments

- **Frank Tacke**, *Charité University, Berlin, Germany*

Drug Targets in Phase 2/3 Trials – Evidence Base and Status Update

09:00 Bile Acid Signaling Pathways (FXR/FGF19)

- **Michael Trauner**, *Medical University of Vienna, Austria*

09:20 Metabolic Pathways: Insulin Signaling, PPARs, THRb 2

- **Rifaat Safadi**, *Hadassah Hebrew University, Israel*

09:45 Trials Targeting Fibrosis

- **Jörn Schattenberg**, *University Medical Center Mainz, Germany*

10:05 Panel Discussion (25 minutes)

10:30 – 11:00 Exhibition & Networking Area/ Rubin & Aquamarin Poster Area

10:30 – 11:00 Coffee Break, Exhibition & Poster Viewing

11:00 – 13:15 Plenary Hall Saphir

11:00 – 12:15 Session 6: Drug Development Overview & Clinical Pharmacology in Practice

Chairs:

Shira Zelber Sagi, *Tel Aviv Medical Center, and School of Public Health, the University of Haifa, Israel*

Jörn Schattenberg, *University Medical Center Mainz, Germany*

Keynote Lecture:

11:00 Why Too Many Strategies are Failing and do not Continue?

- **Arun Sanyal**, *Virginia Commonwealth University, USA*

11:25 DILI in NAFLD: How to Assess if a NASH Drug is Causing Liver Injury

- **Guru Aithal**, *Nottingham University, UK*

11:50 Panel Discussion (25 minutes)



12:15 – 13:15	Non-CME industry symposium (not included in the main event CME/CPD credit offering) See page 40 for session details.
13:15 – 14:15	Exhibition & Networking Area/ Rubin & Aquamarin Poster Area
13:15 – 14:15	Lunch Break, Exhibition & Poster Viewing
14:15 – 16:45	Plenary Hall Saphir
14:15 – 14:40	Keynote Lecture Chair: Quentin Anstee , <i>Newcastle University, UK</i>
	European NAFLD Policy Review • Jeffrey Lazarus , <i>ISGlobal, Hospital Clínic, University of Barcelona, Spain</i>
14:40 – 16:25	Session 7: NAFLD & Malignancy Chairs: Stefan Zeuzem , <i>Goethe University Hospital, Germany</i> Frank Tacke , <i>Charité University, Berlin, Germany</i>
14:40	HCC Surveillance in NAFLD – Who, How and Should You? • Helen Reeves , <i>Newcastle University, UK</i>
15:00	• Extra-Hepatic Malignancies in NAFLD Ramy Younes , <i>University of Turin, Italy</i>
15:20	Mechanisms of Obesity and NASH Related Carcinogenesis • Mathias Heikenwalder , <i>German Cancer Research Center, Germany</i>
	Case Presentation:
15:40	NASH patient with fibrosis F2 that developed HCC. Steatohepatic variant of hepatocellular carcinoma that has interesting immunohistochemistry analysis and progression • Claudia P Oliveira , <i>University of Sao Paulo, Brazil</i>
15:50	Panel Discussion (25 minutes)
16:15 – 16:35	Summary & Closing Remarks